Abivax (NASDAQ:ABVX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Guggenheim in a report released on Tuesday, Benzinga reports. They presently have a $175.00 price objective on the stock. Guggenheim’s target price points to a potential upside of 90.61% from the stock’s current price.
Several other equities research analysts have also issued reports on the stock. BTIG Research increased their price objective on shares of Abivax from $150.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Wedbush dropped their price objective on shares of Abivax from $140.00 to $118.00 and set a “neutral” rating for the company in a research report on Tuesday, September 22nd. Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and increased their price objective for the stock from $108.00 to $158.00 in a research report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Finally, Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $156.69.
View Our Latest Analysis on ABVX
Abivax Stock Up 4.9%
Shares of Abivax stock traded up $4.32 during trading hours on Tuesday, hitting $91.81. The company’s stock had a trading volume of 459,283 shares, compared to its average volume of 1,423,460. Abivax has a 1-year low of $69.81 and a 1-year high of $148.83. The business has a fifty day moving average of $105.79 and a 200 day moving average of $114.49. The company has a market capitalization of $8.04 billion, a PE ratio of -15.15 and a beta of 1.14.
Abivax (NASDAQ:ABVX – Get Free Report) last released its quarterly earnings data on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The firm had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. On average, sell-side analysts anticipate that Abivax will post -4.04 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Two Seas Capital LP purchased a new position in shares of Abivax in the third quarter valued at $66,996,000. Seven Fleet Capital Management LP boosted its stake in shares of Abivax by 218.9% in the first quarter. Seven Fleet Capital Management LP now owns 43,052 shares of the company’s stock valued at $4,794,000 after purchasing an additional 29,553 shares during the period. Militia Capital Management LLC purchased a new position in shares of Abivax in the first quarter valued at $1,893,000. Brummer Multi Strategy AB boosted its stake in shares of Abivax by 56.0% in the first quarter. Brummer Multi Strategy AB now owns 22,428 shares of the company’s stock valued at $2,497,000 after purchasing an additional 8,053 shares during the period. Finally, Readystate Asset Management LP boosted its stake in shares of Abivax by 19.6% in the second quarter. Readystate Asset Management LP now owns 241,530 shares of the company’s stock valued at $32,186,000 after purchasing an additional 39,508 shares during the period. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
About Abivax
Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.
Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.
Read More
- Five stocks we like better than Abivax
- Could Quantinuum’s Breakthrough Make Its Sell-Off a Bargain?
- Wired for Upside: Why Goldman Sachs Upgraded CoreWeave’s Battered Stock
- CarMax’s Double Upgrade Could Signal a Bigger Turnaround
- EHang’s 160% Call Options Surge: What Are Traders Seeing?
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
